JAGUAR HEALTH, INC. Recognition of Deferred Revenue
JAGUAR HEALTH, INC. (JAGX) reported Recognition of Deferred Revenue of $203.19 thousand for the 9-month period ending 2015-09-30, per its 10-Q filed 2015-11-13.
Discontinued › Income Statement › Other Income
us-gaap:RecognitionOfDeferredRevenue · last filed 2015-11-13
- JAGUAR HEALTH, INC. recognition of deferred revenue for the quarter ending 2015-09-30 was $77.67K.
- JAGUAR HEALTH, INC. recognition of deferred revenue for the quarter ending 2015-06-30 was $63.14K.
- JAGUAR HEALTH, INC. recognition of deferred revenue for the quarter ending 2015-03-31 was $62.39K.
- JAGUAR HEALTH, INC. recognition of deferred revenue for the quarter ending 2014-09-30 was $0.00.
| Period end | Recognition of Deferred Revenue 3 month | Recognition of Deferred Revenue 6 month | Recognition of Deferred Revenue 9 month |
|---|---|---|---|
| 2015-09-30 | $77.67K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $140.81K derived: sum of 2 quarters · filed 2015-11-13 | $203.19K 10-Q · filed 2015-11-13 |
| 2015-06-30 | $63.14K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $125.53K 10-Q · filed 2015-08-13 | |
| 2015-03-31 | $62.39K 10-Q · filed 2015-06-26 | ||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $0.00 derived: sum of 2 quarters · filed 2015-11-13 | $0.00 10-Q · filed 2015-11-13 |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $0.00 10-Q · filed 2015-08-13 | |
| 2014-03-31 | $0.00 10-Q · filed 2015-06-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |